A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): Factors associated with B lymphocyte recovery

被引：52
|
作者：
Sutter, Jennifer A. [1 ,2 ]
Kwan-Morley, Jennifer [3 ]
Dunham, Jon [3 ]
Du, Yang-Zhu [1 ,2 ]
Kamoun, Malek [1 ,2 ]
Albert, Daniel [4 ]
Eisenberg, Robert A. [3 ]
Prak, Eline T. Luning [1 ,2 ]
机构：
[1] Univ Penn, Sch Med, Dept Pathol, Stellar Chance Labs 405B, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Lab Med, Stellar Chance Labs 405B, Philadelphia, PA 19104 USA
[3] Univ Penn, Dept Med, Div Rheumatol, Philadelphia, PA 19104 USA
[4] Dartmouth Hitchcock Med Ctr, Rheumatol Sect, Lebanon, NH 03756 USA
来源：
CLINICAL IMMUNOLOGY | 2008年 / 126卷 / 03期
关键词：
B cells; systemic lupus; erythematosus; autoimmunity; human; transitional B cells; immunophenotype;
D O I：
10.1016/j.clim.2007.11.012
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Identifying factors associated with B lymphocyte depletion and recovery may aid the development of individualized treatment regimens, optimizing therapy for patients with autoimmune disease. In this study, 12 patients with active SLE were monitored at baseline and monthly following treatment with rituximab. The number and phenotype of peripheral blood B lymphocytes, T lymphocytes and natural killer cells were correlated with the extent and longevity of B lymphocyte depletion. This analysis generated three candidate biomarkers for lymphocyte monitoring in patients with autoimmune disease who are treated with rituximab: circulating transitional B cells, the K: ratio and natural killer cells. Further refinement of these potential biomarkers may lead to a better understanding of the rote of B cells in disease pathogenesis and a more rational use of B cell depletion therapies. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码：282 / 290
页数：9
相关论文
共 50 条
  • [1] A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): Factors associated with B cell recovery.
    Prak, Eline T. Luning
    Dunham, Jonathan
    Du, Yang-Zhu
    Goodman, Noah
    Khan, Sadia
    Albert, Daniel A.
    Street, Craig
    Kamoun, Malek
    Eisenberg, Robert A.
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S260 - S260
  • [2] SLE-associated transverse myelitis successfully treated with Rituximab (anti-CD20 monoclonal antibody)
    Armstrong, D. J.
    McCarron, M. T.
    Wright, G. D.
    [J]. RHEUMATOLOGY INTERNATIONAL, 2006, 26 (08) : 771 - 772
  • [3] SLE-associated transverse myelitis successfully treated with Rituximab (anti-CD20 monoclonal antibody)
    D. J. Armstrong
    M. T. McCarron
    G. D. Wright
    [J]. Rheumatology International, 2006, 26 : 771 - 772
  • [4] Study of the B- and T-lymphocyte responses in pemphigus patients treated by anti-CD20 immunotherapy (Rituximab).
    Musette, P
    Mouquet, H
    Jacquot, S
    Gilbert, D
    Huetz, F
    Roujeau, JC
    D'Incan, M
    Doutre, MS
    Gorin, I
    Caux, F
    Bedane, C
    Oro, S
    Tron, F
    Joly, P
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2005, 125 (06) : A16 - A16
  • [5] Study of the B- and T-lymphocyte responses in pemphigus patients treated by anti-CD20 immunotherapy (Rituximab)
    Musette, P
    Mouquet, H
    Jacquot, S
    Gilbert, D
    Huetz, F
    Roujeau, JC
    D'Incan, M
    Tron, F
    Joly, P
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2005, 125 (03) : A13 - A13
  • [6] Study of the B- and T-lymphocyte responses in pemphigus patients treated by anti-CD20 immunotherapy (rituximab)
    Musette, P.
    Mouquet, H.
    Jacquot, S.
    Gilbert, D.
    Gougeon, M. L.
    Roujeau, J. C.
    D'Incan, M.
    Bedane, C.
    Tron, F.
    Joly, P.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2006, 126 : 23 - 23
  • [7] DYNAMICS OF B LYMPHOCYTE SUBSETS IN SLE PATIENTS TREATED WITH RITUXIMAB
    Mesnyankina, A. A.
    Aleksandrova, E. N.
    Soloviev, S. K.
    Aleksankin, A. P.
    Glukhova, S. I.
    Novikov, A. A.
    Suponitskaya, E. V.
    Aseeva, E. A.
    Nasonov, E. L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 289 - 289
  • [8] CHARACTERIZATION OF A PATIENTS' ANTIBODIES TO THE ANTI-CD20 THERAPEUTIC RITUXIMAB
    Mahadik, Younis
    Young, Stephen
    Morgan, Matthew
    Gordon, Caroline
    Harper, Lorraine
    [J]. RHEUMATOLOGY, 2012, 51 : 142 - 143
  • [9] Longitudinal analysis of peripheral immune cells in patients with multiple sclerosis treated with anti-CD20 therapy
    Waede, Mie
    Voss, Lasse F.
    Kingo, Christina
    Moeller, Jesper B.
    Elkjaer, Maria L.
    Illes, Zsolt
    [J]. ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2024,
  • [10] DYNAMICS OF B LYMPHOCYTE SUBSETS COUNTS IN SLE PATIENTS TREATED WITH RITUXIMAB
    Mesnyankina, A. A.
    Aleksandrova, E. N.
    Soloviev, S. K.
    Aleksankin, A. P.
    Gluhova, S. I.
    Novikov, A. A.
    Aseeva, E. A.
    Suponitskaya, E. V.
    Nasonov, E. L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1073 - 1073
12345